Sign In
Buy TWST
$91.55
+0.220 (+0.241%)
At Close: Jul 31, 2026
SOUTH SAN FRANCISCO, Calif. & SAN DIEGO--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, and Element Biosciences, Inc., a company democratizin
Twist Bioscience Announces Publication in Science Examining Biosecurity Screening Practices in AI-assisted Protein Design
02:00pm, Thursday, 02'nd Oct 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced the publication in Science of the peer-reviewed p
5 Biotech Stocks Worth Adding to Your Portfolio Now
10:25am, Tuesday, 23'rd Sep 2025
The volatile biotech industry has done reasonably well so far in 2025 amid the ongoing tariff saga. Most pharma/biotech bigwigs are now investing heavily in manufacturing plants/operations in the Unit
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025
12:36pm, Thursday, 18'th Sep 2025
GeneDx, Twist Bioscience and Wave Life Sciences are emerging as key players in the fast-growing genomics and synthetic biology space.
Kuehn Law Encourages Investors of Twist Bioscience Corporation to Contact Law Firm
01:08pm, Monday, 15'th Sep 2025
NEW YORK , Sept. 15, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Twist Bioscience Corporation (NASDAQ: TWST) b
Twist Bioscience to Present at Baird 2025 Global Healthcare Conference
08:00am, Wednesday, 03'rd Sep 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder
Twist Bioscience Collaborates with Synthetic Design Lab
08:00am, Tuesday, 02'nd Sep 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it has collaborated with next generation the
mRNA Biotechs - Long-Term Value Risks Abound
06:20am, Thursday, 28'th Aug 2025
mRNA vaccine companies are overhyped post-pandemic, facing scientific, operational, and regulatory headwinds that limit long-term investment appeal. Scientific and business risks, including delivery c
Twist Bioscience Launches Oncology DNA CGP Panel to Advance Precision Medicine with Customizable, Platform-Agnostic NGS Solution
08:00am, Tuesday, 19'th Aug 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity, in the life sciences segment of the health care sector, today launche
Twist Bioscience: Headwinds Are Mounting
10:56pm, Tuesday, 12'th Aug 2025
Twist Bioscience's growth continues to moderate, in part due to macro headwinds. While Twist's focus on transitioning to profitability in the near-term has significantly reduced cash burn, it has also
After Plunging 33.8% in 4 Weeks, Here's Why the Trend Might Reverse for Twist Bioscience (TWST)
10:36am, Thursday, 07'th Aug 2025
The heavy selling pressure might have exhausted for Twist Bioscience (TWST) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street an
Twist Bioscience Appoints Trynka Shineman Blake to Board of Directors
08:00am, Wednesday, 06'th Aug 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth equity, today announced the appointment of Trynka Shineman Blake to its board of direct
Twist Bioscience Turns The Tide: Q3 Sales Jump, Beats Earnings
03:52pm, Monday, 04'th Aug 2025
What if a biotech company could flip its financial narrative from loss to profit in just a year? Twist Bioscience Corporation TWST has done just that, reporting a surprising third-quarter income that
Twist Bioscience Corporation (TWST) Q3 2025 Earnings Call Transcript
11:06am, Monday, 04'th Aug 2025
Twist Bioscience Corporation (NASDAQ:TWST ) Q3 2025 Earnings Conference Call August 4, 2025 8:00 AM ET Company Participants Adam Laponis - Chief Financial Officer Angela Bitting - Chief Corporate Resp
Twist Bioscience (TWST) Reports Q3 Loss, Tops Revenue Estimates
09:25am, Monday, 04'th Aug 2025
Twist Bioscience (TWST) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to a loss of $0.86 per share a year ago.
